Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Subscribe To Our Newsletter & Stay Updated